Skip to main content

The Hunt for the Missing Endotoxin

Is Outsourcing the Solution to Low Endotoxin Recovery (LER)?

This white paper reviews the causes contributing to low endotoxin recovery (LER), the impact it creates, as well as solutions which can rectify the issues it results in. We also discuss the advantages and disadvantages of developing your de-masking protocols in-house, and how you can use the ENDO-RS® de-masking tool kit to make the process easier from beginning to end. Following this, we outline the pros and cons of outsourcing your de-masking project, what you should look for in a third-party company, and why you can and should trust bioMérieux with your de-masking protocol development.

We spoke to our expert, Dr. Christian Faderl, to find out more about masked endotoxins and how pharmaceutical manufacturers can effectively tackle the problem of LER.

Download White Paper

Filename
LER_In-House_vs_Outsourcing_Whitepaper.pdf
Size
3 MB
Format
application/pdf

   

Related Content

Product

ENDOXPERTS™ Services

ENDOXPERTS™ Endotoxin Services by bioMérieux provide routine testing and feasibility studies as well as specialized services for analytical issues such as LER. Our work for leading pharmaceutical companies has resulted in validated methods for LER, fulfilling regulatory requirements. 

Learn More

Webinar

Low Endotoxin Recovery: Assessment of PDA Technical Report No. 82

The Parenteral Drug Association (PDA) has recently published Technical Report No. 82 (TR82) on the topic of Low Endotoxin Recovery (LER), providing both consensus to the science and data behind the analytical issue, as well as to analytical and mitigation strategies.
Learn More

White Paper

Low Endotoxin Recovery

This case study discusses the Low Endotoxin Recovery (LER) phenomenon in the drug testing and mitigation approach using the ENDO-RS® kit and ENDOLISA® assay for detecting endotoxin interference.

Learn More